文献速递肿瘤 PET/CT

初诊乳腺癌专用18F-FDG PET/MRI的SUV与ADC和预后免疫组化标志物的前瞻性相关性

Prospective Correlation of Prognostic Immunohistochemical Markers With SUV and ADC Derived From Dedicated Hybrid Breast 18F-FDG PET/MRI in Women With Newly Diagnosed Breast Cancer.
PubMed 文献 · Clin Nucl Med · 2021-01-01

结果显示SUV与ADC呈显著负相关,肿瘤分级和Ki67与SUVmean正相关,HER2和雌激素受体与ADC或SUV呈负相关,分子亚型与SUV显著相关。提示同步PET/MRI可能作为识别高危乳腺癌患者的预测工具。

要点

  • SUV与ADC呈显著负相关(r=-0.49至-0.43,均P<0.001)。
  • 肿瘤分级和Ki67与SUVmean正相关(r=0.37和0.32,P<0.01)。
  • 雌激素受体与SUVmax/SUVmean负相关(r=-0.45和-0.42,P<0.001)。

核心结论

  • 乳腺癌原发灶的葡萄糖代谢增高、细胞密度、肿瘤分级、雌激素和HER2表达及分子亚型之间存在相关性。
  • 同步18F-FDG PET与DWI的混合乳腺PET/MRI可能作为初诊分期时识别高危乳腺癌患者的预测工具并指导靶向治疗。

研究设计与样本

  • 所有患者接受俯卧位专用18F-FDG乳腺PET/MRI,DWI(b值0、500、1000 s/mm²)与PET采集同步进行。
  • 在每位患者PET/MRI上勾画涵盖整个原发肿瘤的感兴趣区,测定最大和平均SUV及对应ADC图的平均和最小ADC值。
  • 评估组织病理学肿瘤分级及预后相关免疫组化标志物Ki67、孕激素受体、雌激素受体和HER2。
  • 采用Pearson相关系数比较SUV与ADC值及免疫组化标志物和分子亚型,肿瘤分级比较采用Wilcoxon检验。

主要发现

  • 乳腺PET/MRI衍生的SUV与ADC值呈显著负相关(SUVmean vs ADCmean r=-0.49;SUVmax vs ADCmin r=-0.43;均P<0.001)。
  • 肿瘤分级和Ki67均与乳腺PET/MRI的SUVmean呈正相关(r=0.37和r=0.32,P<0.01)。
  • HER2与乳腺PET/MRI的ADC值呈负相关(r=-0.35,P<0.01)。
  • 分子亚型与SUVmax和SUVmean显著相关(r=0.52和r=0.42,均P<0.05)。
  • 雌激素受体表达与乳腺PET/MRI的SUVmax和SUVmean呈负相关(r=-0.45和r=-0.42,P<0.001)。

临床怎么用

  • 在初诊分期时,同步18F-FDG PET/MRI获得的SUV和ADC值可无创反映肿瘤代谢、细胞密度及预后相关免疫组化特征。
  • SUV与ADC的负相关及与分级、Ki67、雌激素受体、HER2和分子亚型的相关性,可能辅助识别高危乳腺癌患者并指导靶向治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to correlate prognostically relevant immunohistochemical parameters of breast cancer with simultaneously acquired SUVs and apparent diffusion coefficient (ADC) values derived from hybrid breast PET/MRI. PATIENTS AND METHODS: Fifty-six women with newly diagnosed, therapy-naive, histologically proven breast cancer (mean age, 54.1 ± 12.0 years) underwent dedicated prone 18F-FDG breast PET/MRI. Diffusion-weighted imaging (b-values: 0, 500, 1000 s/mm2) was performed simultaneously with the PET acquisition. A region of interest encompassing the entire primary tumor on each patient's PET/MRI scan was used to determine the glucose metabolism represented by maximum and mean SUV as well as into corresponding ADC maps to assess tumor cellularity represented by mean and minimum ADC values. Histopathological tumor grading and prognostically relevant immunohistochemical markers, that is, Ki67, progesterone receptor, estrogen receptor, and human epidermal growth factor receptor 2 (HER2), were assessed. Pearson correlation coefficients were calculated to compare SUV and ADC values as well as the immunohistochemically markers and molecular subtype. For the comparison with the tumor grading, a Wilcoxon test was used. RESULTS: A significant inverse correlation between SUV and ADC values derived from breast PET/MRI (r = -0.49 for SUVmean vs ADCmean; r = -0.43 for SUVmax vs ADCmin; both P's < 0.001) was found. Tumor grading and Ki67 both showed a positive correlation with SUVmean from breast PET/MRI (r = 0.37 and r = 0.32, P < 0.01). For immunohistochemical markers, HER2 showed an inverse correlation with ADC values from breast PET/MRI (r = -0.35, P < 0.01). Molecular subtypes significantly correlate with SUVmax and SUVmean (r = 0.52 and r = 0.42, both P's < 0.05). In addition, estrogen receptor expression showed an inverse correlation with SUVmax and SUVmean from breast PET/MRI (r = -0.45 and r = -0.42, P < 0.001). CONCLUSIONS: The present data show a correlation between increased glucose metabolism, cellularity, tumor grading, estrogen and HER2 expression, as well as molecular subtype of breast cancer primaries. Hence, simultaneous 18F-FDG PET and diffusion-weighted imaging from hybrid breast PET/MRI may serve as a predictive tool for identifying high-risk breast cancer patients in initial staging and guide-targeted therapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Morawitz J, Kirchner J, Martin O, et al. Prospective Correlation of Prognostic Immunohistochemical Markers With SUV and ADC Derived From Dedicated Hybrid Breast 18F-FDG PET/MRI in Women With Newly Diagnosed Breast Cancer. Clin Nucl Med. 2021. PMID: 33351505. doi:10.1097/RLU.0000000000003488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。